Skip to content
← Full study record

NCT02918357 · OUTCOME

Sensitivity on a Per-region Basis

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence · Source last updated 2019-12-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of sensitivity
Interval / dispersion
95% Confidence Interval
Time frame
1 month

What was measured

Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.

Analysis population: Eighty-four patients had confirmed histopathology region validation for this analysis

Groups in this outcome

Ga-68 Labeled PSMA-11 PET

PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later. Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ga-68 Labeled PSMA-11 PET84

Reported measurements

Source class 1
Values in percentage of sensitivity · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Ga-68 Labeled PSMA-11 PET0.90Not reported0.820.95Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.82
        upper Limit
        0.95
        value
        0.90
denoms
  1. counts
    1. group Id
      OG000
      value
      84
    units
    Participants
description
Sensitivity, on a per-region basis of 68Ga-PSMA-11 PET for detection of tumor location confirmed by histopathology/biopsy was calculated. The 95% CI was calculated using the Wilson score method.
dispersion Type
95% Confidence Interval
groups
  1. description
    PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later. Ga-68 labeled PSMA-11 PET: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
    id
    OG000
    title
    Ga-68 Labeled PSMA-11 PET
param Type
NUMBER
population Description
Eighty-four patients had confirmed histopathology region validation for this analysis
reporting Status
POSTED
time Frame
1 month
title
Sensitivity on a Per-region Basis
type
SECONDARY
unit Of Measure
percentage of sensitivity

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice